Whalesbook
Q4 Results Overview
Biocon's fourth-quarter results for FY26 show a sharp drop in net profit, largely due to accounting factors and a high comparison base from the prior year. However, the company’s core biosimilar business demonstrated resilience, as it prepares for a leadership transition.
Profit Decline vs. Adjusted Performance
Biocon reported a net profit of Rs 126 crore for Q4 FY26, down 63.5% from Rs 345 crore a year earlier. This fall was mainly due to the lack of high generic lenalidomide sales from the previous year and an exceptional item this quarter. Revenue from operations grew a modest 2.3% to Rs 4,517 crore from Rs 4,417 crore. EBITDA fell 5.4% to Rs 1,020 crore, and margins narrowed to 22.6% from 24.4%. This was less severe than market watchers had expected.
Adjusted for the one-time impact of Q4 FY25 lenalidomide sales, Biocon’s results are more positive. Adjusted total income rose 10% year-on-year to Rs 4,569 crore, with adjusted EBITDA up 29% to Rs 1,073 crore, and margins improving to 23%. Adjusted net profit before exceptional items surged 64% to Rs 179 crore. For the full fiscal year 2026, adjusted total income was Rs 17,270 crore. EBITDA grew 25% to Rs 3,798 crore, and net profit before exceptional items jumped 323% to Rs 436 crore.
Leadership Transition Planned
Alongside these results, Biocon announced an upcoming management transition. Executive Chairperson Kiran Mazumdar-Shaw is set to hand over leadership to her niece, Claire Mazumdar. This succession will occur over a phased, five-year period, with Mazumdar-Shaw stating she is not retiring immediately. Claire Mazumdar, CEO of US oncology firm Bicara Therapeutics, brings experience in biotech, venture capital, and corporate strategy. She led Bicara to a Nasdaq listing in 2024. Her background guiding Bicara through growth and a public offering makes her well-suited for Biocon’s future strategy.
High Valuation Compared to Peers
Despite adjusted operational resilience and a strong biosimilar division, Biocon's current valuation seems high compared to its peers. As of early May 2026, Biocon’s market capitalization was around Rs 61,700 crore, with a trailing twelve months (TTM) P/E ratio between 72x and 95x. This compares to competitors like Zydus Lifesciences (19.2x P/E), Lupin (22.9x P/E), and Aurobindo Pharma (23.2x P/E). This high valuation suggests investors expect significant future growth, placing scrutiny on Biocon’s ability to meet ambitious targets and manage the leadership transition.
Challenges and Risks Ahead
Biocon’s biosimilar segment is a key growth driver, with 12% revenue growth in Q4 FY26 and making up about 60% of overall revenue. Other segments face challenges. Its CRDMO arm, Syngene, saw revenue rise 2% year-on-year in Q4 FY26 to Rs 1,037 crore, and full-year revenue grow 3% to Rs 3,739 crore, with a 25% EBITDA margin. The generics business faces ongoing competition. The company also continues significant R&D investment, a necessary but costly area in biopharmaceuticals. Integrating its biosimilar and generics businesses to create a unified entity introduces operational complexity and execution risks. A recent U.S. FDA pre-license inspection at Biocon's biosimilars site is a routine but critical regulatory check that could affect future product approvals and market access.
Analyst Outlook and Growth Drivers
Analysts hold a generally positive view of Biocon, with a consensus rating leaning towards 'Moderate Buy' or 'Buy'. The average 12-month analyst price target is around Rs 435.00, suggesting a potential 21% upside from recent levels. However, some analysts are more cautious, with targets between Rs 380–430, indicating a 'Neutral' recommendation. Key growth drivers include the performance of its Humira biosimilar in the US and the revenue growth of Syngene’s research services. Investors will watch how the new leadership handles competitive pressures, regulatory environments, and drives innovation across Biocon's portfolio.